UNSPSC 51384513: Mexoprofen

This classification denotes a nonsteroidal antiinflammatory drug, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3I63VC13V0. European Medicines Agency schedules Mexoprofen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08933MIG. Mexoprofen generally arises in the molecular formula C16H22O2.

UNSPSC 51384513 Mexoprofen is a Commodity code nominally covering a specific nonsteroidal anti-inflammatory drug product, but recent state and local solicitations tagged with this code do not reflect pharmaceutical ingredient procurement. Instead, the opportunities show activity in broader pharmaceutical and health-product distribution, including naloxone procurement, direct-to-manufacturer prescription programs, and generic multi-source pharmaceutical contracting through cooperative purchasing vehicles. State and local governments are using this code — or codes near it in the taxonomy — to solicit finished pharmaceutical products, OTC supplies, and pharmacy benefit program support rather than the specific active pharmaceutical ingredient the code name denotes. The issuing bodies span county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving Minnesota, Oregon, and other participants). Work under the code involves supply of finished products through authorized wholesaler channels, compliance with FDA manufacturing standards and Drug Supply Chain Security Act requirements, and negotiated pricing models.

Recent opportunities reflect activity concentrated in the South and Upper Midwest. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building, with responses due July 26, 2023. Texas HHS Commission posted RFI HHS0017013 on April 3, 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescription program, representing exploratory market research ahead of formal solicitation. Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products with proposals due March 26, 2026 and contract effectiveness targeted for July 1, 2026; awarded vendors must maintain relationships with authorized wholesalers and comply with cGMP and DSCSA standards. The cooperative purchasing vehicle suggests continued activity across multiple jurisdictions and state agencies.